EverSource Wealth Advisors LLC Boosts Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

EverSource Wealth Advisors LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 38.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,082 shares of the company’s stock after purchasing an additional 859 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Takeda Pharmaceutical were worth $43,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Mondrian Investment Partners LTD grew its position in shares of Takeda Pharmaceutical by 47.9% in the 1st quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company’s stock worth $169,119,000 after buying an additional 3,912,569 shares during the last quarter. OLD Mission Capital LLC increased its position in shares of Takeda Pharmaceutical by 1,440.9% during the fourth quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock worth $14,863,000 after purchasing an additional 973,935 shares in the last quarter. Cowen AND Company LLC purchased a new stake in shares of Takeda Pharmaceutical during the 2nd quarter valued at $6,866,000. Capital Research Global Investors lifted its holdings in shares of Takeda Pharmaceutical by 3.6% during the 4th quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after purchasing an additional 503,446 shares during the last quarter. Finally, Van ECK Associates Corp boosted its position in shares of Takeda Pharmaceutical by 27.3% in the 1st quarter. Van ECK Associates Corp now owns 1,684,760 shares of the company’s stock worth $23,401,000 after purchasing an additional 360,844 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 0.8 %

Shares of NYSE:TAK opened at $14.54 on Friday. The business’s 50-day moving average is $14.45 and its 200 day moving average is $13.76. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.63. The firm has a market capitalization of $46.02 billion, a P/E ratio of 26.44, a P/E/G ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. The firm had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.